[Study on effectiveness of carmofur (Mifurol) in @entity5464 , especially XXXX , as a post-operative adjuvant chemotherapeutic agent].

@entity1 @entity5464 @entity448 @entity150 @entity11221 @entity1487
This study was carried out to evaluate the effects of carmofur ( @entity11221 ), a masked compound of @entity1487 ( @entity1487 ), in preventing postoperative recurrence of @entity5464 (especially in @entity150 ). Carmofur was given orally at the dose of 300 approximately 600 mg/day to 134 @entity1 (90 males and 44 females) after the resection. Out of 134 @entity1 , 121 @entity1 were evaluable and the rate of their recurrence was 10.7%. The rate of cumulative nonrecurrence for 65 @entity1 it was 96.0, 73.0 and 60.8% in 1, 2 and 3 years, respectively. The group of curative resection demonstrated a higher cumulative nonrecurrence rate than that of noncurative or palliative resection group. In considering the resection methods, transurethral resection of @entity150 group demonstrated a higher rate than partial or total cystectomy. The average concentration of @entity1487 in serum was 0.65 microgram/ml at 120 minutes after oral administration of 200 mg of carmofur. Moreover, the concentration of @entity1487 (15 approximately 35 micrograms/ml) in urine was higher than that of carmofur. The rate of side effects that appeared was 19.6%. The side effects were hot feeling (12.2%), pollakisuria (4.3%), @entity448 (4.3%), an antabuse-like reaction by drinking (3.8%) and so on. These results were similar to those already reported.
